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Abstract 
Purpose: This study was carried out to investigate the role of hypoxia-inducible factor (HIF) in diabetic 
cardiomyopathy in vitro. 
Methods: Hypoxia was induced chemically in H9C2 cells (cardiac hypertrophy model), and the cells 
were treated with phenylephrine (PE), deferoxamine (DFO), PE + DFO, and HIF-1α siRNA under 
conditions of high and normal glucose. Western blot was used to analyze the expression of some 
glycolytic proteins, including Glut-1, hexokinase (HXK-2), and enolase, while apoptosis of H9C2 was 
determined by flow cytometry. 
Results: PE caused hypertrophy in H9C2, which was ameliorated by HIF-1α. Compared to normal, 
under prolonged high glucose, the low expression of HIF-1α led to low expressions of Glut-1, HXK-2 
and enolase. However, expression of HIF-1α decreased, while those of Bax and Caspase 3 increased, 
and Bcl-2 expression decreased. Furthermore, under short time high glucose, HIF-1α caused apoptosis 
of hypertrophic cardiomyocytes. 
Conclusion: HIF-1 mediates diabetic myocardial hypertrophy, probably as a function of the degree of 
high glucose exposure and hypoxia. 
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Cardiac hypertrophy is one of the characteristic 
features of heart failure [1,2]. In cardiac 
hypertrophy, growth of cardiac tissue and 
maintenance of its function are associated with 
capillary angiogenesis. The survival of 
endothelial cells is mainly maintained by growth 
factors including vascular endothelial growth 
factor (VEGF) [3,4], which plays an important 
role in the regulation of physiological and 
pathological processes in angiogenesis. It is 
known that specific knockout of VEGF can lead 
to decreased density of myocardial capillaries 
and systolic dysfunction [5,6]. In pathological 
cardiac hypertrophy, myocardial cells hold back 
the release of VEGF and bring down 
angiogenesis, thereby contributing to lack of 
oxygen and increased oxygen consumption. The 
hypoxia caused by this process firstly results in 
elevation of hypoxia inducible factor (HIF), which 
in turn leads to increases in levels of VEGF and 
other angiogenic factors. This adaptive response 
delays progression from pathological cardiac 
hypertrophy to heart failure. In early cardiac 
hypertrophy, stability of HIF-1 promotes 
glycolysis, which improves glucose utilization and 
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allows for maintenance of normal functioning of 
the heart [7]. 
 
HIF is an important transcription factor involved 
in the regulation of about 300 genes which play 
important roles in the development of tissues and 
organs, proliferation and differentiation of cells, 
cellular energy metabolism, tumorigenesis and 
tumor progression [8,9]. HIF has three α subunits 
(HIF-1α, HIF-2α and HIF-3α) and a β subunit 
[10,11]. In general, the β subunits in stable 
expression, and is usually polymerized with HIF-
α to form a heterodimer, which is transferred to 
the nucleus. HIF-1 is degraded through the 
ubiquitin-proteasome pathway, which process is 
mediated by the binding of HIF-1 and pVHL [12]. 
However, under hypoxic conditions, HIF-1 cannot 
be recognized by pVHL, a situation which helps 
HIF escape from degradation and get 
transported to the nucleus for binding to hypoxia 
response element (HRE) and the coactivator 
p300. Then the transcription of HIF-1 is initiated 
to offer the molecular foundation of the rapid 
response to hypoxia. It has been reported that 
HIF-1α expression in patients with ischemic heart 
disease is increased, whereas systemic knockout 
of HIF-1α can lead to cardiac hypertrophy and 
even death of embryos. Moreover, cardiac-
specific knockout of HIF-1α can bring about 
changes in angiogenesis, energy availability, 
calcium flux and cardiac systolic function under 
normal oxygen conditions [13]. 
 
A large number of reports indicate that diabetes 
is closely related to angiogenesis. Diabetes or 
hyperglycemia disrupts HIF-mediated cardiac 
hypertrophy adaptive regulatory mechanism [14]. 
In diabetic retinopathy, abnormal increase of 
angiogenesis is directly related to elevated VEGF 
expression [15]. However, reduced expression of 
VEGF and its receptor in people with diabetic 
trauma, induces insufficient angiogenesis 
[16,17].  
Cardiac hypertrophy caused by cardiac overload 
increases oxygen consumption, but when the 
amount of oxygen is reduced, it results in cardiac 
hypoxia. This process accelerates the activation 
of HIF-1, resulting in increase in levels of VEGF 
and other angiogenic factors and enhancement 
of glucose metabolism, which promotes 
angiogenesis and energy metabolism. These 
events delay the progression from cardiac 
hypertrophy to heart failure. So far, many studies 
have shown that diabetes is harmful to the heart. 
Short-term hyperglycemia may promote HIF-1 
activation, which in turn increases the expression 
of VEGF, HXK-2, Glut-1 and enolase [18], but 
long-term hyperglycemia damages the function 
of HIF-1.  
 
The role of HIF in diabetic cardiac hypertrophy is 
essentially unexplored. This study was carried 
out to investigate if HIF plays any role in diabetic 




Induction of cardiac hypertrophy 
 
Cardiac hypertrophy was induced in H9C2 
cardiomyocytes with phenylephrine (PE) (Sigma) 
[19], and deferoxamine (DFO) (Sigma) was used 
to induce the expression of HIF. HIF-1α was 
silenced with siRNA technology. The cells were 
cultured in normal-sugar medium and high-sugar 
medium (Invitrogen). Under three states of 
normal glucose (NG), high glucose (HG) and 
HIF1-α silence the expression of HIF-1α, HIF-2α, 
Glut-1, enolase, HXK-2, Bax and Bcl-2 in H9C2 
cardiomyocytes were measured [20], as well as 
apoptosis of the H9C2 cells. 
 
Cell line and culture 
 
We used H9C2 cardiomyocytes from ATCC. The 
cells were cultured in DMEM containing 10 % 
heat-inactivated fetal bovine serum and 1 % 
penicillin–streptomycin mixture, and were grown 
at 37 °C under a humidified atmosphere of 5 % 




We dissolved 200 pM siRNA in a selective 
medium MEM, which was mixed with liposome 
2000 for 25 minutes at room temperature. This 
was then added to each well of a six-well plate 
containing 5 × 105 H9C2 cardiomyocytes, and 
incubated for 4-6 h. Following that, antibiotic-free 
DMEM medium was replaced after 24 h 
incubation.  
 
Western blot analysis 
 
PE, PE + DFO, PE + DFO and HIF-1α siRNA 
were separately used to treat the H2C9 
cardiomyocytes under conditions of high glucose 
(HG) and normal glucose (NG) for 48 h. The cells 
were harvested and lysed in RIPA buffer with 
protease inhibitors. Protein concentration was 
determined by the Coomassie brilliant blue 
method. Equal amounts of total cell lysates (60 
mg protein) and Full-Range Rainbow Molecular 
Weight Marker were resolved using 12 % sodium 
dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred 
onto polyvinylidene fluoride (PVDF) membranes 
through electrophoresis. PVDF membranes were 
immersed in blocking solution (5 % skim milk) to 
block non-specific binding for 1 h at room 
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temperature. Thereafter, the PVDF membranes 
were immuno-blotted with primary monoclonal 
antibodies at 1:300 dilution at room temperature 
for 2 h, then overnight at 4 oC. Following this, 
further incubation was conducted for 2 h at room 
temperature with rabbit anti-mouse horseradish 
peroxide (HRP)-conjugated secondary antibody 
(1:3000 dilution). The protein-antibody complex 





After digesting with EDTA-free trypsin, the H9C2 
cells were centrifuged at 1000 rpm for 5 min. 
After discarding the medium, the cells were 
washed three times with PBS. Thereafter an 
appropriate amount of binding buffer was added 
to achieve a dilution resulting in a concentration 
of 105 cells per 100 μL. In the dark, 5 μL Annexin 
V-FITC and 3 μL PI were added to 100 μL cells 
and stained for 10 min. Following that, 400 μL 
binding buffer was added. The fluorescence 
intensity of FITC was determined (λEx/Em = 
488/515 nm), and apoptosis of cells was 





Experimental data are expressed as mean ± 
standard deviation (SD) after quantitation or 
semi-quantitation. Comparisons were analyzed 
using one-way analysis of variance (ANOVA). P 
< 0.05 was taken as statistically significant. 
Statistical analysis was performed using SPSS 





Phenylephrine-induced hypertrophy of H9C2 
 
Under an optical microscope (Figure 1), the 
control displayed normal features of H9C2 cells, 
with spindle shape, round and large-centered 
nucleus and small cell interval. H9C2 
cardiomyocytes incubated with PE for 48 h were 
much larger and circular, round or elliptical in 
shape. Moreover, significant expansion of the 
cytoplasm, large cell interval and bigger nucleus 
were observed. 
 
HIF-1α relieved cardiomyocytes hypertrophy 
 
After culturing in 1 % serum medium for 12 h, 
H9C2 cells were treated with PE (100 μM) and 
DFO (200 μM) respectively for 48 h. Then HIF-1α 
gene was silenced with liposome 2000. Under an 
optical microscope (Figure 2), in the case of NG, 
PE caused mild hypertrophy of myocardial cells, 
which was relieved after adding DFO to induced  
HIF-1α. In the HG group, cardiomyocytes treated 
with PE exhibited obvious myocardial 
hypertrophy, which was not mitigated by adding 
DFO due to HG-blockage of HIF-1α activation. 
Moreover, the hypertrophy in myocardial cells 





Figure 1: PE-induced hypertrophy of H9C2 
cardiomyocytes. From top to bottom are normal 
cardiomyocytes, cardiomyocytes treated with PE, 
respectively 
 
Effect of HIF-1α on expression of proteins 
associated with glycolysis 
 
As shown in Figure 3, silencing of HIF-1α gene 
resulted in reduced expression of Glut-1, HXK-2 
and enolase. In the NG and HG groups, 
myocardial hypertrophy occurred after treatment 
with PE, and in the groups administered with 
DFO, HIF-1α expression was relatively higher 
than in the groups treated with PE only. In 
addition, SiRNA reduced the expression of HIF-
1α. HG decreased the activation of HIF-1α, 
which led to lower expression of HIF-1α in this 
group than in the NG group. Administration of 
DFO to the HG group resulted in corresponding 
decrease in the expression of Glut-1. Long-term 
HG treatment led to decreased expression of 
HXK-2 but treatment with DFO increased the 
expressions of HXK-2 and enolase. 
 
Effect of HIF-1α on the expression of proteins 
associated with apoptosis 
 
As shown in Figure 4, compared with the normal 
group, HIF expression was reduced, while Bax 
increased, Bcl-2 decreased and activated 
caspase3 was higher in the long-term HG group. 
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Figure 2: Relief of cardiomyocyte hypertrophy by HIF-1α (NG is the group treated with normal glucose medium; 
HG is the high glucose medium; PE was treated t with PE only; PE + DFO group received  simultaneously PE 
and DFO ; PE + DFO + Si-RNA group got PE and DFO simultaneously for 48 hours, prior to silencing the HIF-1α 




Figure 3: Effect of PE on HIF-1α induced reduction in expression of Glut-1, HXK-2 and enolase under normal 




Figure 4: Effect of PE under normal glucose (NG) and high glucose (HG) on expression of apoptosis-related 
proteins in H9C2 cells 
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Figure 5: HIF-1α mediated cell apoptosis in diabetic myopathy. The lower left corner of each box represents 
living cells. Cells in the lower left corner, top right corner and lower right corner are living cells, necrotic cells and 
early apoptotic cells, respectively 
 
Evidence of apoptosis from flow cytometry 
 
Results from flow cytometry are shown in Figure 
5. HIF-1α mediated the apoptosis of the 
hypertrophic cardiomyocytes exposed to short-




Previous studies have shown that high 
expression of heart HIF-specific transgene 
prevented myocardium structural disorder and 
myocardial fibrosis in mice and exhibited the 
decrease of VEGF, HXK-2 and Glut-1 caused by 
diabetes [18]. Enhanced HIF-1α promotes 
antioxidant capacity of the heart and prevents the 
occurrence of diabetic cardiomyopathy. 
However, cardiac hypertrophy associated with 
pressure lowers HIF-1α [7]. Cell culture studies 
have demonstrated that high glucose conditions 
block HIF-1α activation, thereby blocking 
adaptation to hypoxia. The current study is based 
on earlier investigations on the role of HIF in 
myocardial hypertrophy under high glucose 
conditions in vitro cell culture experiments 
[19,21,22]. We used PE to establish the cardiac 
hypertrophy model, and DFO was given to mimic 
a hypoxic environment necessary for HIF 
production. Moreover, gene silencing technology 
was used to silence HIF-1α. Under NG, the PE-
treated cells displayed slight hypertrophy, but 
after treatment with DFO, cell morphology was 
restored. While HG made myocardial 
hypertrophy more obvious, even DFO-induced 
HIF-1α did not significantly mitigate the 
hypertrophy. This is consistent with previous 
studies stating that high glucose is detrimental to 
the activity of HIF [18]. HIF-1α silencing did not 
change cell morphology substantially, which 
further indicates that HIF-1α has a protective 
effect on myocardial hypertrophy [18]. 
 
In the pathogenesis of heart failure, as well as 
the physiological function of blood vessels, 
significantly altered glucose and lipid metabolism 
is associated with heart failure [14]. The 
transition from aerobic metabolism to glycolysis 
is one of the key cellular processes for adaption 
to hypoxia response, which is regulated by HIF-
1. Therefore, we examined the expression of 
glycolytic proteins using Western Blot. The 
decrease in HIF-1α resulted in reduced 
expression of Glut-1, HXK-2 and enolase. 
Hypoxia can easily induce apoptosis, so it was 
necessary to study the expressions of apoptosis-
related proteins as well. The results obtained 
showed that Bax expression was increased, 
while that of Bcl-2 decreased, and activated 
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caspase 3 was higher under long-term high 
glucose condition. The results suggest that high 
glucose levels impair HIF activity, and that HIF 
protected the H9C2 cells from apoptosis. 
 
However, results of flow cytometry indicated that 
HIF-1 promoted cell apoptosis under short-term 
high glucose condition, which is at variance with 
the western blot results on apoptosis-associated 
proteins. The reason for this apparent 
contradiction is not very clear, but it may be 





Short-term hyperglycemia may contribute to 
activation of HIF-1, which in turn increases the 
expression of VEGF, HXK-2 and Glut-1. 
However, long-term high blood sugar may be 
detrimental to the function of HIF-1. It can be 
inferred from our results that HIF-1 is likely to 
play an important role in diabetic cardiac 
hypertrophy. On account of different effects of 
HIF-1 under different glucose loads and hypoxia, 
it is concluded that HIF may play a pathogenic 
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